Reps Schrier, Langworthy Introduce Bipartisan Bill to Lower Prescription Drug Costs by Expanding Access to Biosimilars
Expedited Access to Biosimilars Act eliminates unnecessary regulatory hurdles while preserving the FDA's authority to require additional